Human Vaccines & Immunotherapeutics (Jan 2023)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence

  • Giancarlo Ripabelli,
  • Angelo Salzo,
  • Manuela Tamburro

DOI
https://doi.org/10.1080/21645515.2023.2168947
Journal volume & issue
Vol. 19, no. 1

Abstract

Read online

Dear Editor, We would like to reply to “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11years: Correspondence” regarding our article entitled “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5–11years: Results from an active pharmacovigilance study in central Italy.”